Tender detail

Non-exclusive rebate agreement for natalizumab infusion solution concentrate

Summary

DAK-Gesundheit intends to conclude non-exclusive rebate agreements with pharmaceutical companies for medicines containing natalizumab, limited to concentrate for solution for infusion (ATC L04AG03). The agreements run from 1 December 2026 to 30 November 2028, but end earlier if an exclusive agreement for the active ingredient takes effect.

Reference number
497cdacf-b371-4e74-a948-c4dad449a0d4
Buyer
Country
Germany (DEU)
Procedure
Open procedure
CPV
33600000 Pharmaceutical products
Deadline
2028-10-05
Status
Open
Contract subject
Supplies
Estimated value
1,00 EUR
Source
DEU_BKMS

More tender information after sign-in

The public view shows key tender details. Sign in to open official links, documents and AI tender support.